ONE-WAYOngoing theme · still written in the latest filings
Risk that the efficacy of cord blood treatments remains unconfirmed
Risk that prolonged clinical research, review and efficacy assessment of cord blood treatments, together with insufficient confirmation of treatment efficacy, will impede clinical application and commercialization.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.